NEWARK, NJ--(Marketwired - Jan 15, 2014) - BioNeutral Group, Inc. (OTCBB: BONU) (OTCQB: BONU)
Last month we released to you the news of two of our channel partners, ProSell Sales Representatives and BioTech Medical, Inc. for the industrial and health care segments of our relevant marketplaces. As we mentioned then, we are excited about these relationships and look forward to the potential for these professionally managed organizations. Both organizations are off to a good start. Within the industrial segment, our Ygiene™ offers unique efficacy properties over existing products for mold remediation, and most recently ProSell is developing relationships around the country with local owners of maintenance supply outlets that cater to mold contractors. In the health care market segment BioTech Medical is beginning to make important inroads as well.
During the fourth quarter of last year, we were focused on the upfront training and initial development of these two organizations as well as developing new ones, news of which we should be releasing shortly.
Our focus for the first half of 2014 will be to continue to expand our selling effort to include additional sales partners as well as additional market segments. In that regard, we are engaged in active discussions with other potential independent selling organizations as well, both here at home and abroad.
Along with adding to our selling organizations, we will in 2014 be conducting additional testing to improve our product label claims for Ygiene™ to broaden Ygiene's market potential by extending its reach and heightening its competitiveness. Lastly we plan in the coming year to begin to explore additional opportunities for our Ogiene™ line.
In conclusion, while our sales in 2013 were sparse, we gained the important visibility to begin to attract the highly qualified partners necessary in order to penetrate many of these relatively long lead time, and in the health care market particularly, organizationally complex organizations. Side by side with our partners, our overall plan for '14 is to broaden our reach into our markets by multiples by leveraging the relationships and awareness we built in 2013 and adding to them. We will continue to report our progress in these areas as it occurs
Thank you for your support in 2013 and we look forward to it in the future as well.
About BioNeutral Group, Inc.
Headquartered in Newark, New Jersey, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, YGIENE™ and OGIENE™ kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the YGIENE™ brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutral.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to YGIENE-206. BioNeutral's antimicrobial formulations will be marketed under the brand name YGIENE™ and are available for sale in the United States.